Surrozen (SRZN) Gains from Investment Securities (2020 - 2026)
Surrozen (SRZN) recorded quarterly Gains from Investment Securities of $41.1 million in Q1 2026, up 14.92% quarter-over-quarter from $35.8 million in Q4 2025, and up 10387.5% on a YoY basis from N/an in Q1 2025.
Surrozen (SRZN) Gains from Investment Securities (2020 - 2026) Analysis & Trends
Surrozen's Gains from Investment Securities history runs 7 years deep, the most recent figure standing at $41.1 million for Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 10387.5% year-over-year to $41.1 million; the TTM figure through Mar 2026 stood at $96.6 million (up 24550.26% YoY), while the FY2025 annual figure was $1.3 million, up 136.75% from the prior year.
- Gains from Investment Securities was $41.1 million for Q1 2026 at Surrozen, up from $35.8 million in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $41.1 million in Q1 2026 to a low of -$6.5 million in Q1 2022.
- Historically, Gains from Investment Securities has averaged $6.0 million across 5 years, with a median of $392000.0 in 2025.
- Biggest YoY gain for Gains from Investment Securities was 838861.04% in 2023; the steepest drop was 101.57% in 2023.
- A 5-year view of Gains from Investment Securities shows it stood at $8.2 million in 2022, then slumped by 101.57% to -$128000.0 in 2023, then surged by 15475.78% to $19.7 million in 2024, then surged by 81.77% to $35.8 million in 2025, then increased by 14.92% to $41.1 million in 2026.
- The last three Gains from Investment Securities figures came in at $41.1 million (Q1 2026), $35.8 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Surrozen | 235,841.47 | -106.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.11 Mn |
| Mar 31, 2026 | 41.11 Mn |
| Dec 31, 2025 | 35.77 Mn |
| Dec 31, 2025 | 35.77 Mn |
| Sep 30, 2025 | 1.24 Mn |
| Sep 30, 2025 | 1.24 Mn |
| Jun 30, 2025 | 1.22 Mn |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | 392,000.00 |
| Mar 31, 2025 | 392,000.00 |
| Dec 31, 2024 | 19.68 Mn |
| Dec 31, 2024 | 19.68 Mn |
| Sep 30, 2024 | 9,000.00 |
| Sep 30, 2024 | 9,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Mar 31, 2024 | 63,000.00 |
| Mar 31, 2024 | 63,000.00 |
| Dec 31, 2023 | -128,000.00 |
| Dec 31, 2023 | -128,000.00 |